In the same way, Gourgouli and colleagues described in a total of 52 neovascular AMD patients that the ARMS2/A69S genotype, carriers of the risk variant, experienced significantly worse treatment outcomes compared to wild-type patients [142]. The gene discussed is ARMS2; the disease is age-related macular degeneration.